Canton Labs hit with US FDA Import Alert at Indian API plant

By Dan Stanton

- Last updated on GMT

Related tags Fda import alert Pharmaceutical drug

Canton Labs hit with US FDA Import Alert at Indian API plant
The US FDA has banned imports of drug products made at Canton Laboratories’ Baroda, India plant weeks after the plant was pulled up for data failures.

The API plant received a Warning Letter​ in February after the US Food and Drug Administration (FDA) observed cGMP violations that included a number of breaches of data integrity, and - as of Thursday – all products have been banned from being imported into the US.

The Import Alert - which allows the FDA to detain without physical examination any product from the facility including antimicrobial agents, reagents, fumigants, pH control agents, as well as APIs and formulated drug products – is the same charge as has befallen a number of Indian drug facilities of late.

Last week, Canadian firm Apotex​ had products manufactured at its Bangalore plant banned from being imported, whilst in March Sun Pharma​ had the same sanctions imposed on its facility in Karkhadi. In the past year, products have also been banned from import at Wockhardt​ and Ranbaxy​ facilities in India.

Amongst the problems described in the Warning Letter were a number of examples which raised “serious concerns regarding the integrity, reliability and accuracy of the data generated and available”​ at the plant.

This included, the failure to perform laboratory testing of APIs to ensure conformance to specifications and to accurately report results on Certificates of Analysis (CoA), the failure to maintain complete data derived from all laboratory tests, the failure to ensure equipment is cleaned in a reproducible and effective manner to prevent contamination, and the failure to ensure that APIs are produced according to pre-approved instructions.

“Our inspection revealed serious documentation practices and reported missing raw data,”​ the FDA said. “It is a basic responsibility of your quality unit to ensure that all API lots produced meet specifications that they are purported to possess.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more